Abbott Labs | StockChase
106
Abbott Labs (ABT-N)

Last Price Recorded: $55.8000 on 2017-11-23

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical

Abbott Labs


Signal Opinion Expert
     

2017-10-10

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick May 17/17. Up 28%.) He likes that this isn’t a “one trick pony”. It has devices, diagnostics, nutrition, etc. A broad, diversified franchise, in a sector he approves of. Thinks it continues to make a lot of sense.

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Management

Price: $55.400
Owned: Yes

2017-06-15

BUY on WEAKNESS
Abbott Labs (ABT-N)

She continues to hold it and likes it.  They have done well this year so she would wait for a pull back to add to this position.  They are good at taking costs out.  They always increase their dividend and it should continue.  A good core holding.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $48.120
Owned: Yes

2017-05-17

TOP PICK
Abbott Labs (ABT-N)

Healthcare, as a sector, is neutral to tilting positively. Within that though, there are some industry groups that he likes, and some he doesn’t like. This one is in the subsector of medical devices, and is a great diversified player in that space. Their acquisition of St. Jude broadens their business and cardiovascular. Dividend yield of 2.4%. (Analysts’ price target is $48.)

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Management

Price: $43.080
Owned: Yes

2017-05-10

COMMENT
Abbott Labs (ABT-N)

Had owned this in the past. They made a number of acquisitions, so patience is required. Acquired St. Jude, which he had seen losing market share to Boston Scientific. One concern is that they bloated out their balance sheet for this acquisition. Trading at about 18X, so not terribly inexpensive. Also, there are still some balance sheet risk. If you are a long-term player, they have a proven ability to execute on their operations, and it will likely get re-rated.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $44.500
Owned: No

2017-03-21

BUY
Abbott Labs (ABT-N)

This fits the profile of the type of company he would want to be adding to, on days like today. It is in the sector that is tremendously out of favour. The healthcare sector was the only sector that had a negative return last year. It has started to be a little more resilient this year, but relative to the history of healthcare, valuations are far more reasonable. He likes this because it has a history and a culture of growing the dividend. They have a wonderful brand name. 2.4% dividend yield.

biotechnology/pharmaceutical
David Dietze

Founder, Pres. & Chief Investment Strategist, Point View Wealth Management

Price: $44.800
Owned: Unknown

2017-02-22

COMMENT
Abbott Labs (ABT-N)

This is sitting at around 17.5X forward earnings. The St. Jude acquisition was a big one for them. It expanded their balance sheet. They still have the Alere acquisition overhang. Have some things to chew through this year in order to get the multiple expansion up to something like 21X, where its direct competitors would trade at. If a longer-term holder, you do have some upside on this.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $45.010
Owned: Unknown

2016-09-13

WAIT
Abbott Labs (ABT-N)

This does branded generics, nutritionals and medical devices. Their branded generics have good exposure to emerging markets, areas that need the drugs but don’t necessarily have the money to pay for the branded version. A well diversified company run by great management. They have announced 2 acquisitions. The overhang on the stock is that if they do both transactions, they may have to issue equity to fund some of that.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $40.640
Owned: Yes

2016-08-17

COMMENT
Abbott Labs (ABT-N)

Healthcare is one of the sectors in the broad N.A. market that is heavily out of favour. This is in the healthcare and equipment space, and is not one of those business that is deeply, deeply undervalued right now. It is in the process of trying to do a merger, and he is very reticent about recommending a stock that is in the process of having a merger in the US. He would much prefer an Allergan (AGN-N) where there is no potential deal risk at all. Abbott Labs is trading at 20X this year’s earnings, and Allergan is trading at about 18X, and is a much bigger growth story. Dividend yield of 2.33%. (See Top Picks.)

biotechnology/pharmaceutical
Bruce Tatters

Founding Partner and CIO, Triumph Asset Management

Price: $44.680
Owned: Unknown

2016-07-28

DON'T BUY
Abbott Labs (ABT-N)

Significant emerging markets exposure.  He sees better risk reward in other parts of the healthcare market.

biotechnology/pharmaceutical
Andy Nasr

VP & Investment Strategist, Sentry Investments

Price: $44.450
Owned: No

2016-06-22

COMMENT
Abbott Labs (ABT-N)

Has 4 businesses, an established pharma, labs division, diagnostic division and a medical device division. Has owned this for some time. Recently made a couple of acquisitions, so the valuation hasn’t kept up with its peers. Part of the reason is because of hair on some of the acquisitions. They are looking to acquire another company for about $5 billion + $3 billion in debt, which would be complementary to their monitoring devices. Their larger acquisition is St. Jude Medical, highly complementary and a leader in cardiac rhythmic management. Paid $25 billion with about $5 billion debt. This is going to be cash and stock. A situation where patience is required. You have 6 months of a bit of noise around the acquisitions, and after that they will be integrated and begin their growth. He is writing options on this.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $38.740
Owned: Yes

2016-06-14

BUY
Abbott Labs (ABT-N)

Acquiring St. Jude Medical to enhance their stent products, and Alere, which is a diagnostic company. The stock pulled back when they announced the St. Jude acquisition, as it is quite large. The company will probably have to issue some equity to fund both acquisitions. She really likes management. This is an attractive entry point.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $37.660
Owned: Yes

2016-06-01

BUY
Abbott Labs (ABT-N)

Has not performed very well of late. He likes it going forward as well as their acquisition of St. Jude’s Medical, which will be accretive to the bottom line. This would be a nice time to pick up some shares.

biotechnology/pharmaceutical
Matthew McCall

President, Penn Financial Group

Price: $39.500
Owned: Unknown

2016-05-18

COMMENT
Abbott Labs (ABT-N)

Emerging markets represents about 40% of their earnings. Have a very strong branded generic division and a lot of that is in the emerging-market, so currency has been a huge head wind for them. Also, have a leading adult and infant nutritional business as well as medical devices. There was some concern that the medical device area was not growing as fast as some of their other businesses. Management is quite competent they can get things improving.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $37.750
Owned: Yes

2016-05-11

DON'T BUY
Abbott Labs (ABT-N)

Healthcare is a great sector, but the worst performing one year-to-date. Politicians are talking about capping prices for healthcare manufacturers, which doesn’t help. More importantly, Medicare and Medicaid US administrations are trying to cap prices and this one is being hit particularly hard. There are better names in this space.

biotechnology/pharmaceutical
John Burke

CEO & CIO, Burke Financial Strategies

Price: $38.010
Owned: Unknown

2016-02-09

COMMENT
Abbott Labs (ABT-N)

Abbott Labs (ABT-N) or Johnson & Johnson (JNJ-N)? She likes healthcare as an overall investment because of the demographics. They both have FX headwinds because they are both international. Emerging markets is about 40% of this company’s revenues. If you want a diversified health care company that gives you an attractive yield, she would go with J&J.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $37.000
Owned: Yes

Showing 1 to 15 of 106 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.